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Abstract: Multiple sclerosis (MS) is a disease of the central nervous system with both an 
inflammatory and degenerative component. The disease primarily affects young adults and 
results in significant physical and cognitive disability. Several disease-modifying agents are 
currently used in the management of multiple sclerosis. Glatiramer acetate (GA, Copaxone
®, 
co-polymer 1) is a disease-modifying agent approved for the treatment of relapsing remitting 
multiple sclerosis. Apart from its unique mode of action, there is evidence pointing toward a 
possible neuroprotective role. This review will critically discuss GA’s potential mechanisms of 
action, the results of clinical trials, safety profile, and future directions of treatment. 
Keywords: multiple sclerosis, disease-modifying agents, glatiramer acetate, clinical trials, 
MRI, neurodegeneration
Introduction
Most patients with multiple sclerosis (MS) present with an initial inflammatory phase 
manifested by relapses and gadolinium-enhancing lesions on magnetic resonance 
imaging (MRI) followed by a gradually progressive degenerative phase. A minority 
of patients have the progressive form of the disease from the onset. Even though 
the etiology and pathogenesis of the disease are largely unknown, several clinical 
trials have confirmed a favorable response to treatment with immunomodulating and 
immunosuppressive agents. Several disease-modifying agents are currently available 




®), and glatiramer 
acetate (Copaxone
®). Mitoxantrone (Novantrone
®), an immunosuppressant, is used for 
the treatment of worsening MS. Natalizumab (Tysabri
®), a selective adhesion molecule 
inhibitor, was approved for a short period of time prior to being withdrawn because 
three patients, two of whom were in MS trials and one of whom was in a Crohn’s 
disease study, developed progressive multifocal leukoencephalopathy (PML) (Yousry 
et al 2006). At the time of writing this review, natalizumab is being re-evaluated for 
approval. However, if approved, it will likely initially be utilized in a select group of 
patients.
All these agents have a marked effect on the inflammatory component of the disease 
and have been shown to alter the natural history of MS. Unfortunately, effects on the 
degenerative aspect of the disease have not been consistently demonstrated. Glatiramer 
acetate (GA) is different from the interferons in having a unique mechanism of action 
and there is emerging evidence that it may also have an effect on the neuro-degenerative 
aspect of MS. This article reviews the available data supporting the use of glatiramer 
acetate in relapsing remitting MS.
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Immunology of MS
Current hypotheses support the idea that MS is an 
immunologically mediated disease. Although the etiology is 
unknown, it is likely that exposure to a variety of antigens, 
including viruses and toxins, results in activation of T cells. 
These T cells (T helper 1) recognize antigens presented 
by antigen-presenting cells and subsequently release pro-
inflammatory cytokines, such as tumor necrosis factor (TNF), 
inferferon-γ, and IL-12, and then subsequently invade the 
central nervous system (CNS). In the CNS, T cells are further 
activated by antigens found on antigen-presenting cells, which 
leads to further secretion of pro-inflammatory cytokines and 
chemokines. A variety of proposed mechanisms may then 
lead to demyelination and axonal transaction (Martin et al 
2001) (Table 1).
effect, as GA appeared to prevent the induction of EAE.
Evidence suggests that the structural similarity between 
GA and MBP may be partly responsible by way of competi-
tive mechanisms and/or cross-reactivity for the therapeutic 
benefit of GA. EAE studies suggest that GA may compete 
with MBP for antigenic binding to the MHC II complex on 
antigen-presenting cells in the CNS. This mechanism alone is 
unlikely to function in vivo because GA is rapidly degraded 
after subcutaneous administration before it can enter the CNS 
(Lobel et al 1996).
  However, this competition may function 
in vivo if it occurs in the periphery or at subcutaneous SC   
injection site where GA may confront MBP-specific T cells 
before GA is degraded. The resulting GA/MHC complex 
may then bind preferentially to MBP-specific T cells over 
MBP/MHC complexes and induce alterations to the T cells. 
One such alteration may be a phenotypic shift in the T cells 
from Th1 to Th2 cells, thus increasing anti-inflammatory 
mechanisms (Duda et al 2000; Chen et al 2001; Neuhaus 
et al 2001). 
 After activation in the periphery by daily 
immunization, GA has been demonstrated to selectively 
promote trans endothelial migration of Th2 cells across the 
blood–brain barrier (BBB) (Prat et al 2005). It is postulated 
that when the GA-specific Th2 cells are reactivated in the CNS 
by the presentation of degraded myelin components, they are 
stimulated to release anti-inflammatory cytokines such as 
IL-4, IL-6, and IL-10 (Neuhaus et al 2001). The release of 
anti-inflammatory cytokines then nonspecifically decreases 
the pathological inflammation in MS (Miller et al 1998; 
Brenner et al 2001; Dhib-Jalbut 2002; Yong 2002) (Figure 1).
GA and neuroprotection
The burden of disease in MS appears to be propagated by 
more than just inflammation and secondary demyelination 
from acute relapses. An important mechanism in MS appears 
to be a parallel ongoing process of neuro-degeneration. 
Data pointing towards neurodegeneration as a significant 
component of the immunopathology of the initial phases 
of MS are increasing (Trapp et al 1998). The mechanism 
of this neuronal degeneration is unknown and represents an 
important area of interest and a potential target for future 
therapeutics (Neuhaus et al 2003).
Much of the interest in potential mechanisms of 
neuroprotection surround the role of neurotrophic factors, 
particularly brain-derived neurotrophic factor (BDNF). 
BDNF is up-regulated in response to neuronal damage 
and may have a protective role against neuro-degeneration. 
BDNF is hypothesized to influence the neuronal response 
to trauma or degeneration via inhibition of cell death and 







Others (viruses, bacteria, free radicals)
History of GA and mechanism of 
action
An important step in understanding the immune mechanisms 
in MS was the development of an animal model of demyelina-
tion. Experimental allergic encephalomyelitis (EAE), a T 
cell-mediated disease, can be induced in susceptible animals 
by inoculating them with CNS tissue such as myelin basic 
protein (MBP) (Bernard et al 1992). Copolymers (copolymer 
1 up to copolymer 11) were synthesized with amino acid 
composition similar to MBP. None of them were able to 
induce EAE but several were able to prevent or minimize 
EAE in animals inoculated with MBP. Copolymer 1 (L-
glutamate, L-tyrosine, L-alanine, and L-lysine) appeared to 
be the most potent and showed a consistent effect in several 
animal models, including primates (Teitelbaum et al 1971). 
It was also shown to be safe.
effect of GA on T cells
GA is a synthetic molecule composed of four amino acids 
(L-alanine, L-glutamic acid, L-lysine, and L-tyrosine). 
These are the same amino acids represented in MBP. GA 
was originally designed as a synthetic model of MBP for the 
purpose of inducing EAE, an experimental animal model of 
MS. However, in vitro studies proceeded to show the opposite international Journal of Nanomedicine 2006:1(3) 285
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axonal degeneration, and via support of oligodendrocytes 
and remyelination. Studies have shown BDNF’s ability to 
rescue degenerating neurons by inducing axonal outgrowth, 
remyelination, and regeneration (Gravel et al 1997; Yan et 
al 2002).
In situ data have demonstrated increased BDNF 
expression from immune cells isolated from MS lesions 
(Kerschensteiner et al 2003)
 and studies on interferon-β-
treated MS patients show higher BDNF production compared 
with healthy volunteers (Petereit et al 2003).
 Given these 
observations, BDNF may be a potent neurotrophic factor with 
the ability to greatly impact neuronal repair and regrowth 
(Thoenen 1995; Barde 1997).
It is possible that GA may also mediate a neuroprotective 
role via increased production of neurotrophic factors such 
as BDNF. Evidence has shown that locally activated GA-
reactive Th2 cells produce BDNF ( Ziemssen et al 2002). In 
GA-treated EAE-induced mice, brain regions demonstrating 
high populations of GA-specific T cells also had high levels 
of BDNF and Th2 anti-inflammatory cytokines (Aharoni et 
al 2003). Another study found a reduced level of BDNF in 
the serum and CSF of RRMS patients which was reversed 
after therapy with GA (Azoulay et al 2005).
GA antibodies
Neutralizing antibodies to interferons is associated with 
worsening clinical efficacy and MRI parameters. Although 
patients treated with GA develop binding antibodies, there 
is no evidence that the antibodies influence the therapeutic 
effect of the drug (Farina et al 2002).
Figure 1  A simplified diagrammatic representation of the immunopharmacology of GA in MS therapeutics. The Pre-rx portion of the panel emphasizes the baseline 
state in MS with CD4+ Th1 myelin antigen-reactive cells being activated by systemic antigen processing cells, including macrophages, that present foreign antigens 
that are myelin-like (‘myelin’ Ag) in the context of surface MHC to TCr; invoking the concept of molecular mimicry. Stimulated CD4+ Th1 ‘myelin’ Ag-reactive 
cells secrete a number of pro-inflammatory cytokines (iL-2, iFN-γ, TNF-α, and LT). with GA therapy, GA may displace some ‘myelin’ Ag. More importantly, on 
presentation and stimulation of GA and ‘myelin’ Ag-reactive CD4+ Th1 cells, GA silences cross-reacting CD4+ Th1 ‘myelin’ Ag-reactive cells through anergy, 
apoptosis, or antigen-specific mechanisms. Concomitantly, GA stimulates and expands a population of GA-reactive CD4+ Th1 cells (dark grey curved arrows). 
with continued therapy the net result is a reduced proportion of CD4+ Th1 and an increased proportion of GA and ‘myelin’ cross-reactive CD4+ Th2 cells. when 
these GA and ‘myelin’ cross-reactive CD4+ Th2 cells gain access to the CNS by trafficking across the blood–brain barrier, they are re-stimulated by true myelin 
Ags processed and presented by microglia, a brain-resident macrophage. On re-stimulation, the GA-reactive CD4+ Th2 cells secrete anti-inflammatory cytokines 
to inhibit ‘myelin’ Ag-reactive CD4+ Th1 cells within the CNS and also secret topic factors, such as BDNF that may facilitate neuronal survival (light grey curved 
arrow). reproduced from wolinsky JS 2004a. Glatiramer acetate for the treatment of multiple sclerosis. Expert Opin Pharmacother, 5:875–91. Copyright © 2004 with 
permission from Ashley Publications. 
Abbreviations: Ag, antibody; BDNF, brain-derived neutrophic factor; GA, glatiramer acetate; iFN, interferon; LT, leukotriene; MHC, major histocompatibility 
complex; MS, multiple sclerosis; rx, treatment; TCr, T cell receptor; TNF, tumor necrosis factor. international Journal of Nanomedicine 2006:1(3) 286
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Clinical trials
Copolymer 1 was initially studied in a small group of patients 
with advanced MS and acute disseminated encephalomyelitis 
(ADE). Even though there was no clear benefit noted it was 
found to be safe and well tolerated (Abramsky et al 1977). 
Another preliminary trial (Phase 1, open-label) suggested 
a beneficial effect and no significant toxicity (Bornstein et 
al 1982).
The first randomized study of copolymer 1 involved 48 
patients in 24 pairs matched for age, sex, and disability. Two 
additional unmatched patients were also enrolled, raising 
the total number of patients to 50. Patients on copolymer 
had fewer relapses and more patients remained relapse-free 
(Bornstein et al 1987). Copolymer was then tested in a more 
disabled chronic progressive population consisting of both 
secondary progressive and primary progressive patients. 
After a pretrial observation period, 106 out of 169 patients 
were noted to have progression and were entered in the trial. 
Although the results were not statistically significant there 
was a trend favoring the patients who received copolymer 
(Bornstein et al 1991).
In 1991, a Phase 3, double-blinded, placebo-controlled 
study began with 251 patients. The primary endpoint was the 
mean number of relapses in subjects receiving GA compared 
with placebo. The Expanded Disability Status Scale (EDSS) 
range was 0–5.0. The mean annualized relapse rate was 0.59 
for patients receiving GA and 0.84 for patients receiving 
placebo (29% reduction) (Johnson et al 1995). On the basis of 
this trial, GA was approved for treatment of RRMS.
 After 10 
years of open label extension, patients originally randomized 
to GA continue to do better than patients who were originally 
on placebo. Patients continuing GA for 10 years had an 
average disease duration of 18 years, yet nearly all remained 
ambulatory. Only 108 of the original 251 patients remained 
in the study and the annualized relapse rate in both (GA-GA, 
placebo-GA) declined to 0.2 (Ford et al 2006).
 
MRI effects of GA therapy
MRI provides a non-invasive surrogate marker of pathology, 
and is the only way subclinical disease activity can be 
detected. MRI has improved diagnostic accuracy, advanced 
the understanding of immunopathology of MS, and has 
become an essential tool in clinical drug trials. The first 
study of the effects of GA on serial MRI involved 10 
RRMS patients compared before and after treatment. GA 
reduced both frequency and area of new lesions (Mancardi 
et al 1998).
 The larger US Pivotal Trial included only a few 
patients undergoing MRI but did demonstrate a reduction in 
enhancing lesions, and it also showed that delay in treatment 
was associated with increased progression on MRI (Wolinsky 
et al 2001). Since the Phase 3 trial of GA did not include 
a significant MRI component, a large randomized, double-
blinded, placebo-controlled MRI trial was initiated in Canada 
and Europe. A total of 239 patients were randomized to GA 
or placebo for 9 months followed by an open-label phase 
for an additional 9 months. The European/Canadian MRI 
study demonstrated a reduction in frequency and volume of 
new enhancing lesions, with a 29% reduction in the number 
of enhancing lesions for the treatment arm. This study also 
observed an intriguing difference in the rapidity of resolution 
of gadolinium (Gd)-enhancing activity between GA-treated 
patients and interferon-β-treated patients. Enhancing 
activity resolved much more slowly in the GA-treated 
group (Comi et al 2001; Wolinsky et al 2002).
 This slower 
resolution may provide further support for current theories 
on the differential mechanisms of GA and interferon-β. Gd-
enhancing MRI activity generally corresponds with BBB 
disruption (Bakshi et al 2004). While interferon-β functions 
by reducing lymphocytic infiltration across the BBB, GA 
activity is dependent upon the entry of GA-reactive Th2 cells 
beyond an intact BBB. From within the CNS, GA-reactive 
Th2 cells then decrease inflammation and repair the BBB. 
This mechanism of repair from within the CNS is proposed 
to take a longer time, as reflected by the delayed change in 
MRI activity (Dhib-Jalbut 2002).
Several recent MRI studies raise the possibility of 
neuroprotection as a potential mechanism of GA. Axonal 
degeneration in MS is represented on MRI by atrophy and 
the conversion of hyperintense T2 lesions into persistent 
hypointense T1 lesions. In the natural history of MS, 
20%–60% of new lesions will degenerate into persistent 
hypointense T1 lesions (van Waesberghe et al 1998). The 
European/Canadian study demonstrated that the percentage 
of new lesions evolving into so called “T1-black holes” was 
more than 50% lower in the GA-treated group (Filippi et al 
2001).
 Thus, in addition to slowing the formation of new MS 
lesions, GA may also limit permanent damage of new lesions 
by protecting axons and promoting lesion recovery.
The effects of GA on generalized brain atrophy in RRMS 
have also come under recent attention. The pilot study (27 
patients from the pivotal Phase III trial) to assess MRI-
measured atrophy demonstrated a significantly lower mean 
reduction in brain volume in patients on GA. The placebo 
group had a three-fold greater decline in brain volume 
compared with the GA group (Ge et al 2000). This study was 
limited because of relatively small number of patients and international Journal of Nanomedicine 2006:1(3) 287
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lack of baseline data. In a larger study population (European/
Canadian trial), the findings were mixed depending on the 
MRI brain volume measurement techniques. When the 
European/Canadian MRI data were analyzed by a semi-
automated segmentation technique, no significant difference 
in atrophy was found (Rovaris et al 2001).
 However, when 
the same MRI data were re-analyzed using a fully automated, 
normalized technique, the analysis demonstrated a slight but 
not significantly lowered brain volume change in the GA 
group. However, during the open-label phase, there was a 
significant reduction in atrophy for the group initially treated 
with GA (Sormani et al 2004).
 These data may suggest a 
delayed but significant effect of GA on brain atrophy.
 Further 
research may better answer this question.
Meta-analysis, comparative, 
combination, and other trials
When data from three clinical trials (Bornstein pilot trial, US 
pivotal trial, and European Canadian study) were compiled 
for meta-analysis, an annualized relapse rate reduction of 
28% was noted for GA compared with placebo (Boneschi 
et al 2003).
Several comparative open label trials have supported the 
use of GA as a first-line agent (Table 2). These trials should 
be interpreted with caution since biases are unavoidable. 
Controlled trials comparing the efficacy of GA and inteferon-
β are underway. Data for use as combination treatment are 
lacking, but a large NIH-funded trial looking at the efficacy 
of a combination of GA and interferon-β1a is currently 
underway.
When all the randomized and controlled GA trials were 
analyzed in a Cochrane database review, GA did not show 
a significant effect on disease progression as measured by 
a worsening on EDSS score. The authors could not support 
GA as first-line treatment in MS (Munari et al 2004).
 This 
study’s reliability could have been limited for several reasons 
including the variability of disease course (a mixture of 
RRMS, secondary progressive MS, and primary progressive 
MS) and the reliability of EDSS as a primary outcome 
measure.
GA was also studied in primary progressive MS and 
a large controlled trial failed to provide any evidence for 
benefit in this population (Wolinsky 2004b; Wolinsky 
et al 2004).
 Similarly, an oral form of GA studied in a 
controlled population did not show any significant evidence 
of efficacy. 
Safety
The most common adverse reaction is a local injection-
site reaction of erythema and induration.
 In one trial, 90% 
experienced at least one such reaction compared with 69% 
of placebo patients. GA is less frequently associated with 
a transient post-injection systemic reaction of flushing, 
chest tightness, dyspnea, chest palpitations, and anxiety. 
This self-limited systemic reaction was experienced in 
15%. The reactions typically resolve within 15–30 minutes 
without sequelae. No significant laboratory abnormalities 
Table 2  Comparative open-label trials on the use of GA as a first-line agent
Author  Nr patients  Comparative treatment groups  Duration  Results
Khan et al 2001  156  iFN β1a 30 µg/week iM (n = 40)  18 months
    iFN β1b 250 µg/qod SC (n=41)
    GA 20 mg/day SC (n=42)
    No treatment (n=33) 
Carra et al 2003  134  iFN β1a 30 µg/week iM (n=26)  16 months
    iFN β1a 44 µg 3x/week (n=20)
    iFN β1b 250 µg/qod SC (n=20)
    GA (n=30) daily SC 
    No treatment (n=38)
Fletcher et al 2002  58  GA daily SC  2 years
    GA qod SC
    Untreated
 
Haas et al 2003  283  iFN β1a 30 µg/week iM (n=79)  2 years
    iFN β1a 22 µg 3x/week SC (n=48)
    iFN β1b 250 µg/qod SC (n=77)
    GA daily SC (n=79)
 
Abbreviations: GA, glatiramer acetate; iFN, interferon; iM, intra-muscular; SC, subcutaneous. 
relapse rate reduction was significant in 
the GA and iFN β1b groups
Significant decline in relapse rates in all 
patients with the largest reduction in the 
GA group
All patients showed similar reduction in 
relapse rates compared to 2 years prior to 
immunomodulating therapy
Significant reductions from pre-study to 
on-study relapse rates for all of the iFN 
preparations with superior reduction in 
GA relapse rate compared with interferons 
at month 24international Journal of Nanomedicine 2006:1(3) 288
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were found.
 According to the manufacturer, rare cases of 
non-fatal anaphylaxis have also been reported. Sixty-six 
non-fatal anaphylactic reactions in about 80 000 treated 
patients have been reported worldwide (Rauschka et al 2005).
 
GA is a pregnancy category B drug. Although its use is not 
recommended in pregnancy, there is no evidence to suggest 
increased risk of adverse fetal or pregnancy outcome (Coyle 
et al 2003).
Conclusion
Since the initial pilot trial of GA published in 1987, numerous 
clinical trials have consistently established its safety and 
efficacy as a first-line treatment of RRMS. Its role in reducing 
clinical activity of disease has also been supported by parallel 
MRI data. Laboratory and clinical studies have also helped 
to define its potential mechanisms of action, including a 
potentially unique mechanism of neuroprotection. Results 
of ongoing clinical trials may define its role in combination 
therapy as well as its efficacy in comparison with other 
established therapies. Future studies may also help to define 
other potential clinical applications of GA in the treatment 
of MS and other autoimmune disorders.   
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